Notice of Meeting for the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC), 79938-79939 [2024-22545]
Download as PDF
<![CDATA[
79938
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 25, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–22438 Filed 9–30–24; 8:45 am]
BILLING CODE 4140–01–P
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–22526 Filed 9–30–24; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute on Drug Abuse;
Notice of Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
L conflict SEP.
Date: November 5, 2024.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research.
Date: November 12, 2024.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting for the
Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC)
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The Secretary of Health and
Human Services announces a meeting of
the Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC).
The meeting will provide information
on federal efforts related to serious
mental illness (SMI) and serious
emotional disturbance (SED); and
Report Outs from Focus Area 1—Data
and Evaluation; Focus Area 2—Access
and Engagement; Focus Area 3—
Treatment and Recovery; Focus Area
4—Criminal Justice, and Focus Area 5—
Finance; and updates on SAMHSA’s
initiatives.
DATES: October 29, 2024, 9:00 a.m. to
4:00 p.m. (EDT)/Open.
ADDRESSES: The meeting is open to the
public and can be accessed virtually
only by accessing: https://
www.zoomgov.com/j/1604912525?pwd=
XrfbvgFJM7BnfEq1xJIHRgiIsCKaEF.1 or
by dialing 646–828–7666, webinar ID:
160 491 2525, passcode: 689916.
Agenda with call-in information will be
posted on the SAMHSA website prior to
the meeting at https://www.samhsa.gov/
about-us/advisory-councils/meetings.
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Pamela Foote, ISMICC Designated
Federal Officer, SAMHSA, 5600 Fishers
Lane, Rockville, MD 20857; telephone:
240–276–1279; email: pamela.foote@
samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background and Authority
The ISMICC was established on
March 15, 2017, in accordance with
section 6031 of the 21st Century Cures
Act, and the Federal Advisory
Committee Act, 5 U.S.C. App., as
amended, to report to the Secretary,
Congress, and any other relevant federal
department or agency on advances in
SMI and SED, research related to the
prevention of, diagnosis of, intervention
in, and treatment and recovery of SMIs,
SEDs, and advances in access to services
and supports for adults with SMI or
children with SED. In addition, the
ISMICC will evaluate the effect federal
programs related to SMI and SED have
on public health, including public
health outcomes such as: (A) rates of
suicide, suicide attempts, incidence and
prevalence of SMIs, SEDs, and
substance use disorders, overdose,
overdose deaths, emergency
hospitalizations, emergency room
boarding, preventable emergency room
visits, interaction with the criminal
justice system, homelessness, and
unemployment; (B) increased rates of
employment and enrollment in
educational and vocational programs;
(C) quality of mental and substance use
disorders treatment services; or (D) any
other criteria determined by the
Secretary. Finally, the ISMICC will
make specific recommendations for
actions that agencies can take to better
coordinate the administration of mental
health services for adults with SMI or
children with SED. Not later than one
(1) year after the date of enactment of
the 21st Century Cures Act, and five (5)
years after such date of enactment, the
ISMICC shall submit a report to
Congress and any other relevant federal
department or agency.
II. Membership
This ISMICC consists of federal
members listed below or their
designees, and non-federal public
members.
Federal Membership: Members
include, The Secretary of Health and
Human Services; The Assistant
Secretary for Mental Health and
Substance Use; The Attorney General;
The Secretary of the Department of
Veterans Affairs; The Secretary of the
Department of Defense; The Secretary of
the Department of Housing and Urban
E:\FR\FM\01OCN1.SGM
01OCN1
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
Development; The Secretary of the
Department of Education; The Secretary
of the Department of Labor; The
Administrator of the Centers for
Medicare and Medicaid Services; the
Administrator of the Administration for
Community Living, and The
Commissioner of the Social Security
Administration.
Non-Federal Membership: Members
include, not less than 14 non-federal
public members appointed by the
Secretary, representing psychologists,
psychiatrists, social workers, peer
support specialists, and other providers,
patients, family of patients, law
enforcement, the judiciary, and leading
research, advocacy, or service
organizations.
The ISMICC is required to meet at
least twice per year.
To attend virtually, submit written or
brief oral comments, or request special
accommodation for persons with
disabilities, contact Pamela Foote.
Individuals can also register at https://
snacregister.samhsa.gov/.
The public comment section will be
scheduled at the conclusion of the
meeting. Individuals interested in
submitting a comment, must notify
Pamela Foote on or before October 18,
2024, via email to: Pamela.Foote@
samhsa.hhs.gov.
Up to three minutes will be allotted
for each approved public comment as
time permits. Written comments
received in advance of the meeting will
be considered for inclusion in the
official record of the meeting.
Substantive meeting information and
a roster of Committee members is
available at the Committee’s website:
https://www.samhsa.gov/about-us/
advisory-councils/ismicc.
Dated: September 26, 2024.
Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2024–22545 Filed 9–30–24; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
khammond on DSKJM1Z7X2PROD with NOTICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines) using
Urine and the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) publishes a notice
listing all HHS-certified laboratories and
Instrumented Initial Testing Facilities
(IITFs) in the Federal Register during
the first week of each month, in
accordance with section 9.19 of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
Section 9.17 of the Mandatory
Guidelines using Oral Fluid. If any
laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/drug-testing-resources/
certified-lab-list.
HHS separately notifies Federal
agencies of the laboratories and IITFs
currently certified to meet the standards
of the Mandatory Guidelines using
Urine and of the laboratories currently
certified to meet the standards of the
Mandatory Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); January 23,
2017 (82 FR 7920); and on October 12,
2023 (88 FR 70768).
The Mandatory Guidelines using Oral
Fluid were first published in the
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
79939
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020, and subsequently
revised in the Federal Register on
October 12, 2023 (88 FR 70814).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid effective
October 10, 2023 (88 FR 70814), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine effective
February 1, 2024 (88 FR 70768), the
following HHS-certified IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Dynacare *, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190 (Formerly: GammaDynacare Medical Laboratories)
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Pages 79938-79939]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22545]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Notice of Meeting for the Interdepartmental Serious Mental
Illness Coordinating Committee (ISMICC)
AGENCY: Substance Abuse and Mental Health Services Administration,
Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Secretary of Health and Human Services announces a meeting
of the Interdepartmental Serious Mental Illness Coordinating Committee
(ISMICC).
The meeting will provide information on federal efforts related to
serious mental illness (SMI) and serious emotional disturbance (SED);
and Report Outs from Focus Area 1--Data and Evaluation; Focus Area 2--
Access and Engagement; Focus Area 3--Treatment and Recovery; Focus Area
4--Criminal Justice, and Focus Area 5--Finance; and updates on SAMHSA's
initiatives.
DATES: October 29, 2024, 9:00 a.m. to 4:00 p.m. (EDT)/Open.
ADDRESSES: The meeting is open to the public and can be accessed
virtually only by accessing: https://www.zoomgov.com/j/1604912525?pwd=XrfbvgFJM7BnfEq1xJIHRgiIsCKaEF.1 or by dialing 646-828-
7666, webinar ID: 160 491 2525, passcode: 689916. Agenda with call-in
information will be posted on the SAMHSA website prior to the meeting
at https://www.samhsa.gov/about-us/advisory-councils/meetings.
FOR FURTHER INFORMATION CONTACT: Pamela Foote, ISMICC Designated
Federal Officer, SAMHSA, 5600 Fishers Lane, Rockville, MD 20857;
telephone: 240-276-1279; email: [email protected].
SUPPLEMENTARY INFORMATION:
I. Background and Authority
The ISMICC was established on March 15, 2017, in accordance with
section 6031 of the 21st Century Cures Act, and the Federal Advisory
Committee Act, 5 U.S.C. App., as amended, to report to the Secretary,
Congress, and any other relevant federal department or agency on
advances in SMI and SED, research related to the prevention of,
diagnosis of, intervention in, and treatment and recovery of SMIs,
SEDs, and advances in access to services and supports for adults with
SMI or children with SED. In addition, the ISMICC will evaluate the
effect federal programs related to SMI and SED have on public health,
including public health outcomes such as: (A) rates of suicide, suicide
attempts, incidence and prevalence of SMIs, SEDs, and substance use
disorders, overdose, overdose deaths, emergency hospitalizations,
emergency room boarding, preventable emergency room visits, interaction
with the criminal justice system, homelessness, and unemployment; (B)
increased rates of employment and enrollment in educational and
vocational programs; (C) quality of mental and substance use disorders
treatment services; or (D) any other criteria determined by the
Secretary. Finally, the ISMICC will make specific recommendations for
actions that agencies can take to better coordinate the administration
of mental health services for adults with SMI or children with SED. Not
later than one (1) year after the date of enactment of the 21st Century
Cures Act, and five (5) years after such date of enactment, the ISMICC
shall submit a report to Congress and any other relevant federal
department or agency.
II. Membership
This ISMICC consists of federal members listed below or their
designees, and non-federal public members.
Federal Membership: Members include, The Secretary of Health and
Human Services; The Assistant Secretary for Mental Health and Substance
Use; The Attorney General; The Secretary of the Department of Veterans
Affairs; The Secretary of the Department of Defense; The Secretary of
the Department of Housing and Urban
[[Page 79939]]
Development; The Secretary of the Department of Education; The
Secretary of the Department of Labor; The Administrator of the Centers
for Medicare and Medicaid Services; the Administrator of the
Administration for Community Living, and The Commissioner of the Social
Security Administration.
Non-Federal Membership: Members include, not less than 14 non-
federal public members appointed by the Secretary, representing
psychologists, psychiatrists, social workers, peer support specialists,
and other providers, patients, family of patients, law enforcement, the
judiciary, and leading research, advocacy, or service organizations.
The ISMICC is required to meet at least twice per year.
To attend virtually, submit written or brief oral comments, or
request special accommodation for persons with disabilities, contact
Pamela Foote. Individuals can also register at https://snacregister.samhsa.gov/.
The public comment section will be scheduled at the conclusion of
the meeting. Individuals interested in submitting a comment, must
notify Pamela Foote on or before October 18, 2024, via email to:
[email protected].
Up to three minutes will be allotted for each approved public
comment as time permits. Written comments received in advance of the
meeting will be considered for inclusion in the official record of the
meeting.
Substantive meeting information and a roster of Committee members
is available at the Committee's website: https://www.samhsa.gov/about-us/advisory-councils/ismicc.
Dated: September 26, 2024.
Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2024-22545 Filed 9-30-24; 8:45 am]
BILLING CODE 4162-20-P
